Search results
Stopping the march: Can effective treatment of psoriasis prevent progression to psoriatic arthritis?
Medical Xpress· 14 hours agoPsoriatic arthritis (PsA) is a chronic inflammatory arthritis which appears in around one-third of...
Exploring whether different joints have different treatment outcomes in cases of psoriatic arthritis
Medical Xpress· 14 hours agoThere are many treatment options for psoriatic arthritis (PsA), and EULAR—The European Alliance of...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
Rhode Island Current via Yahoo News· 1 hour agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Rhode Islanders face massive barriers to health care | Opinion
The Providence Journal via Yahoo News· 7 days agoPaul Adam, of Woonsocket, is the Rhode Island Lead Volunteer for the American Cancer Society Action Network. Psoriatic arthritis controlled my life, taking ...
The Best Products For Treating Psoriasis, According To Dermatologists
HuffPost· 1 day ago“[It] commonly arises on the scalp, ears, elbows, knees and nails,” she said. “In addition to the...
Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu
BioPharma Dive via Yahoo Finance· 3 days agoBoth medicines are TYK2 inhibitors, a group of oral medicines that drugmakers are positioning as...
EULAR 2024 Preview: What's Not to Miss?
Medscape· 3 days agoEULAR 2024 Preview: What's Not to Miss at This Year's Congress? The European Alliance of Associations for Rheumatology (EULAR) 2024 European Congress of...
Johnson & Johnson (NYSE:JNJ) Shares Sold by Core Wealth Advisors Inc.
ETF DAILY NEWS· 3 days agoCore Wealth Advisors Inc. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 9.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission ...
Sei Investments Co. Sells 49,216 Shares of Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 3 days agoSei Investments Co. reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission ...
Inebilizumab 'MITIGATES' Flare Risk in IgG4-Related Disease
Medscape· 6 days agoInebilizumab-cdon reduced the risk for flares by 87% in patients with IgG4-RD, the MITIGATE study showed.